Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity

Journal of Cellular Biochemistry

Volumn 114, Issue 4, 2013, Pages 929-941

  Crasto, Gazelle J ^a   Kartner, Norbert ^a   Yao, Yeqi ^a   Li, Keying ^a   Bullock, Liv ^a   Datti, Alessandro ^b,c   Manolson, Morris F ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

BIOFLAVONOIDS; DRUG DISCOVERY; OSTEOPOROSIS; PROTON TRANSPORT; VACUOLAR H+ ATPase

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATASE; LUTEOLIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL VIABILITY; MONONUCLEAR CELL; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING;

ACTINS; ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SIZE; CELL SURVIVAL; HIGH-THROUGHPUT SCREENING ASSAYS; ISOENZYMES; LUTEOLIN; MICE; MULTIPROTEIN COMPLEXES; NIH 3T3 CELLS; OSTEOCLASTS; OSTEOGENESIS; PROTEIN INTERACTION MAPPING; RECOMBINANT FUSION PROTEINS; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84874230563     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24434     Document Type: Article

References (49)

1. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben A-M, Bracke M, Awad S, John A, Kamalboor HA, Al Sultan MA, Arafat K, Gespach C, Petroianu G,. 2011. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 651: 18-25.
2. Brideau C, Gunter B, Pikounis B, Liaw A,. 2003. Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8: 634-647.
3. Chinnam N, Dadi PK, Sabri SA, Ahmad M, Kabir MA, Ahmad Z,. 2010. Dietary bioflavonoids inhibit Escherichia coli ATP synthase in a differential manner. Int J Biol Macromol 46: 478-486.
4. Choi E-M,. 2007. Modulatory effects of luteolin on osteoblastic function and inflammatory mediators in osteoblastic MC3T3-E1 cells. Cell Biol Int 31: 870-877.
5. +-ATPase. Comparison of proton transport in kidney- and osteoclast-derived vesicles. J Biol Chem 269: 30158-30163.
6. Feng S, Deng L, Chen W, Shao J, Xu G, Li Y-P,. 2009. Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts. Biochem J 417: 195-203.
7. Finnigan GC, Hanson-Smith V, Houser BD, Park HJ, Stevens TH,. 2011. The reconstructed ancestral subunit a functions as both V-ATPase isoforms Vph1p and Stv1p in Saccharomyces cerevisiae. Mol Biol Cell 22: 3176-3191.
8. +-ATPase/ synthase with an essentially drag-free probe. Nat Commun 2: 1-9.
9. Henriksen K, Bollerslev J, Everts V, Karsdal MA,. 2011. Osteoclast activity and subtypes as a function of physiology and pathology-Implications for future treatments of osteoporosis. Endocr Rev 32: 31-63.
10. Hinton A, Bond S, Forgac M,. 2009a. V-ATPase functions in normal and disease processes. Pfluegers Arch/Eur J Physiol 457: 589-598.
11. Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, Sahagian GG, Jay D, Martinez-Zaguilan R, Forgac M,. 2009b. Function of a subunit isoforms of the V-ATPase in pH homeostasis and in vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem 284: 16400-16408.
12. Hong S, Pedersen PL,. 2008. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol Mol Biol Rev 72: 590-641.
13. Kandaswami C, Lee L-T, Lee P-PH, Hwang J-J, Ke F-C, Huang Y-T, Lee M-T,. 2005. The antitumor activities of flavonoids. In Vivo 19: 895-910.
14. +-ATPase a3-B2 subunit interaction. J Biol Chem 285: 37476-37490.
15. Kawasaki-Nishi S, Bowers K, Nishi T, Forgac M, Stevens TH,. 2001. The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis. J Biol Chem 276: 47411-47420.
16. Kim T, Ha H, Kim N, Park E-S, Rho J, Kim EC, Lorenzo J, Choi Y, Lee SH,. 2010. ATP6v0d2 deficiency increases bone mass, but does not influence ovariectomy-induced bone loss. Biochem Biophys Res Commun 403: 73-78.
17. Kim T-H, Jung JW, Ha BG, Hong JM, Park EK, Kim H-J, Kim S-Y,. 2011. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J Nutr Biochem 22: 8-15.
18. +-ATPase activity and expression in mouse bone marrow cultures. J Bone Miner Res 14: 2127-2136.
19. 0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12: 1403-1409.
20. Lee J-W, Ahn J-Y, Hasegawa S-i, Cha B-Y, Yonezawa T, Nagai K, Seo H-J, Jeon W-B, Woo J-T,. 2009. Inhibitory effect of luteolin on osteoclast differentiation and function. Cytotechnology 61: 125-134.
21. Lemieux JM, Wu G, Morgan JA, Kacena MA,. 2011. DMSO regulates osteoclast development in vitro. In Vitro Cell Dev Biol Anim 47: 260-267.
22. Liu A-L, Liu B, Qin H-L, Lee SM, Wang Y-T, Du G-H,. 2008. Anti-influenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa. Planta Med 74: 847-851.
23. +-ATPase subunit Vph1p. J Biol Chem 269: 14064-14074.
24. Manolson MF, Yu H, Chen W, Yao Y, Li K, Lees RL, Heersche JNM,. 2003. The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (≥10 nuclei) and small (≤5 nuclei) osteoclasts. J Biol Chem 278: 49271-49278.
25. Marjuki H, Gornitzky A, Marathe BM, Ilyushina NA, Aldridge JR, Desai G, Webby RJ, Webster RG,. 2011. Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion. Cell Microbiol 13: 587-601.
26. McMichael BK, Kotadiya P, Singh T, Holliday LS, Lee BS,. 2006. Tropomyosin isoforms localize to distinct microfilament populations in osteoclasts. Bone 39: 694-705.
27. Merkulova M, Bakulina A, Thaker YR, Grüber G, Marshansky V,. 2010. Specific motifs of the V-ATPase a2-subunit isoform interact with catalytic and regulatory domains of ARNO. Biochim Biophys Acta 1797: 1398-1409.
28. Miura GI, Froelick GJ, Marsh DJ, Stark KL, Palmiter RD,. 2003. The d subunit of the vacuolar ATPase (Atp6d) is essential for embryonic development. Transgenic Res 12: 131-133.
29. Neri D, Supuran CT,. 2011. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10: 767-777.
30. 2 release via mechanistically distinct process. Br J Pharmacol 130: 1353-1361.
31. Niikura K,. 2007. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis. Cancer Chemother Pharmacol 60: 555-562.
32. Nishi T, Kawasaki-Nishi S, Forgac M,. 2003. Expression and function of the mouse V-ATPase d subunit isoforms. J Biol Chem 278: 46396-46402.
33. Ochotny N, Flenniken AM, Owen C, Voronov I, Zirngibl RA, Osborne LR, Henderson JE, Adamson SL, Rossant J, Manolson MF, Aubin JE,. 2011. The V-ATPase a3 subunit mutation R740S is dominant negative and results in osteopetrosis in mice. J Bone Miner Res 26: 1484-1493.
34. Pangrazio A, Caldana ME, Lo Iacono N, Mantero S, Vezzoni P, Villa A, Sobacchi C,. 2012. Autosomal recessive osteopetrosis: Report of 41 novel mutations in the TCIRG1 gene and diagnostic implications. Osteoporosis Int 271: 3-8.
35. Scimeca J-C, Quincey D, Parrinello H, Romatet D, Grosgeorge J, Gaudray P, Philip N, Fischer A, Carle GF,. 2003. Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Hum Mutat 21: 151-157.
36. Seelinger G, Merfort I, Schempp CM,. 2008. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 74: 1667-1677.
37. 1 motor: Cleavage of ATP at the catalytic site occurs in 1 ms before 40° substep rotation. Proc Natl Acad Sci U S A 100: 14731-14736.
38. Shin D-K, Kim M-H, Lee S-H, Kim T-H, Kim S-Y,. 2012. Inhibitory effects of luteolin on titanium particle-induced osteolysis in a mouse model. Acta Biomater 8: 3524-3531.
39. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis I, Etzioni A, Fasth A, Fisher A, Gerritsen B, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Superti Furga A, Valiaho JA, van Hove JLK, Vihinen M, Vujic D, Vezzoni P, Villa A,. 2001. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 10: 1767-1773.
40. Takahashi N, Udagawa N, Tanaka S, Suda T,. 2003. Generating murine osteoclasts from bone marrow. Methods Mol Med 80: 129-144.
41. Tanaka Y, Nakayamada S, Okada Y,. 2005. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4: 325-328.
42. Toei M, Saum R, Forgac M,. 2010. Regulation and isoform function of the V-ATPases. Biochemistry 49: 4715-4723.
43. +-ATPase: Preferential expression of the a3 isoform during osteoclast differentiation. J Biol Chem 275: 8760-8765.
44. Vojtek AB, Ders CJ,. 1998. Increasing complexity of the Ras signaling pathway. J Biol Chem 273: 19925-19928.
45. Walsh NC, Gravallese EM,. 2010. Bone remodeling in rheumatic disease: A question of balance. Immunol Rev 233: 301-312.
46. Wu H, Xu G, Li Y-P,. 2009. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res 24: 871-885.
47. Zhang J, Ahn M-J, Sun QS, Kim K-Y, Hwang YH, Ryu JM, Kim J,. 2008a. Inhibitors of bone resorption from Halenia corniculata. Arch Pharm Res 31: 850-855.
48. Zhang Z, Zheng Y, Mazon H, Milgrom E, Kitagawa N, Kish-Trier E, Heck AJR, Kane PM, Wilkens S,. 2008b. Structure of the yeast vacuolar ATPase. J Biol Chem 283: 35983-35995.
49. Zhao Y, Yang G, Ren D, Zhang X, Yin Q, Sun X,. 2011. Luteolin suppresses growth and migration of human lung cancer cells. Mol Biol Rep 38: 1115-1119.